Literature DB >> 7173296

Pharmacokinetics of terodiline in human volunteers.

B Karlén, K E Andersson, G Ekman, S Strömberg, U Ulmsten.   

Abstract

The pharmacokinetics of terodiline HCl was studied in nine healthy volunteers given 12.5 mg i.v. and p.o. or 20 mg i.v. and 25 mg p.o. on two different occasions. The serum concentrations were measured by gas chromatography--mas spectrometry, using deuterated terodiline HCl as the internal standard. After i.v. administration the kinetics could be described by a two-compartment model with a mean distribution half life of 0.3 h and a mean elimination half life of 63 h. The serum clearance and apparent volume of distribution varied about 4-fold with mean values of 4.8 1/h and 417 1, respectively. After oral administration, the mean half life of absorption was 0.7 h and that of elimination 65 h. The absolute bioavailability varied between 64% and 105% with a mean of 92%. The long serum half life of terodiline should permit its once daily administration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173296     DOI: 10.1007/bf00547566

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Identification of hydroxylated metabolites of terodiline in animal and man.

Authors:  J Vessman; A Sundwall
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1970

2.  Determination of terodiline (Bicor) in serum by gas chromatography and electron capture detection of benzophenone formed by chromic acid oxidation.

Authors:  J Vessman; S Strömberg
Journal:  Acta Pharm Suec       Date:  1969-11

3.  Drug treatment of the overactive detrusor.

Authors:  K E Andersson; U Ulmsten
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980

4.  Evidence for two catalytically different binding sites of liver microsomal cytochrome P-450: importance for species and sex differences in oxidation pattern of lidocaine.

Authors:  C von Bahr; I Hedlund; B Karlén; D Bäckström; H Grasdalen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-07

5.  A double-blind, cross-over study of the effects of terodiline in women with unstable bladder.

Authors:  G Ekman; K E Andersson; T Rud; U Ulmsten
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980

6.  Calcium antagonistic effects of terodiline in rabbit aorta and human uterus.

Authors:  J R Ostergaard; K Ostergaard; K E Andersson; L Sommer
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980

7.  Anticholinergic and calcium antagonistic effects of terodiline in rabbit urinary bladder.

Authors:  S Husted; K E Andersson; L Sommer; J R Ostergaard
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980

8.  Terodiline inhibition of human bladder contraction. Effects in vitro and in women with unstable bladder.

Authors:  T Rud; K E Andersson; N Boye; U Ulmsten
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980
  8 in total
  4 in total

1.  Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients.

Authors:  B Hallén; A Magnusson; S Bogentoft; P Ekelund
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence.

Authors:  H D Langtry; D McTavish
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

3.  Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence.

Authors:  B Hallén; S Bogentoft; S Sandquist; S Strömberg; G Setterberg; E Ryd-Kjellén
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.

Authors:  S H Thomas; P D Higham; K Hartigan-Go; F Kamali; P Wood; R W Campbell; G A Ford
Journal:  Br Heart J       Date:  1995-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.